New advances of preimplantation and prenatal genetic screening and noninvasive testing as a potential predictor of health status of babies.
The current morphologically based selection of human embryos for transfer cannot detect chromosome aneuploidies. So far, only biopsy techniques have been able to screen for chromosomal aneuploidies in the in vitro fertilization (IVF) embryos. Preimplantation genetic diagnosis (PGD) or screening (PGS) involves the biopsy of oocyte polar bodies or embryonic cells and has become a routine clinical procedure in many IVF clinics worldwide, including recent development of comprehensive chromosome screening of all 23 pairs of chromosomes by microarrays for aneuploidy screening. The routine preimplantation and prenatal genetic diagnosis (PND) require testing in an aggressive manner. These procedures may be invasive to the growing embryo and fetus and potentially could compromise the clinical outcome. Therefore the aim of this review is to summarize not only the new knowledge on preimplantation and prenatal genetic diagnosis in humans, but also on the development of potential noninvasive embryo and fetal testing that might play an important role in the future.
SAGBAL Dr. Shterev, IVF Unit, Hristo Blagoev 25-31, 1330 Sofia, Bulgaria.
Tanya
0000-0002-7222-9651
T
Milachich
D025063:Chromosome Disorders / Q000175:diagnosis* / Q000235:genetics*; D005260:Female; D005544:Forecasting; D005820:Genetic Testing / Q000639:trends*; D006801:Humans; D007231:Infant, Newborn; D011247:Pregnancy; D011256:Pregnancy Outcome / Q000235:genetics*; D019836:Preimplantation Diagnosis / Q000639:trends*; D011296:Prenatal Diagnosis / Q000639:trends*